A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

Amato, Robert J. ; Jac, Jaroslaw ; Giessinger, Sarah ; Saxena, Somyata ; Willis, James P.

Cancer, 2009-06, Vol.115 (11), p.2438-2446 [Periódico revisado por pares]

Hoboken: Wiley Subscription Services, Inc., A Wiley Company

Texto completo disponível